Revlimid
| Name | Revlimid |
|---|---|
| Active Substance | lenalidomide |
| Prescription | na recept |
| Type of prescription | ograničeni recept |
| Distribution | u ljekarni |
| ATC Code | L04AX04 |
| Medicinal product marketed in the Croatia | Da |
| Educational materials for healthcare professionals |
Vodič za zdravstvene radnike, verzija 4 Obrazac pristanka bolesnika, verzija 3 Obrazac prijave trudnoće, verzija 3 |
| Educational materials for patients / caregivers |
Vodic za bolesnike, verzija 4 Kartica za bolesnika, verzija 3 |
Note
The medicinal product has been authorised via centralised procedure in all Member States of the European Union based on the European Medicines Agency's expert opinion. Additional information on the medicinal product can be found under the following link:https://www.ema.europa.eu/en/medicines/human/EPAR/revlimid
The marketing authorisation has been granted by the European Commission. All marketing authorisations of the European Commission can be found under the following link: http://ec.europa.eu/health/documents/community-register/html/index_en.htm
Direct Healthcare Professional Communication
| Name | Date | Download |
|---|---|---|
| Pismo zdravstvenim radnicima o novim važnim preporukama s obzirom na reaktivaciju virusa uz primjenu lenalidomida (Revlimid) | 08.11.2016 | Celgene Europe Limited |
